Research progress in therapy drug monitoring of levetiracetam
- VernacularTitle:左乙拉西坦治疗药物监测的研究进展
- Author:
Chang GAO
1
;
Bin NI
2
;
Fanghui CHEN
2
;
Chunyu GUO
2
;
Guilin WEI
2
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Gannan Medical University，Jiangxi Ganzhou 341001，China;Ganzhou Key Laboratory of Immunotherapeutic Drugs Developing for Childhood Leukemia，Jiangxi Ganzhou 341000，China
2. Dept. of Pharmacy，the First Affiliated Hospital of Gannan Medical University，Jiangxi Ganzhou 341001，China
- Publication Type:Journal Article
- Keywords:
levetiracetam;
therapeutic drug monitoring;
rational drug use;
plasma concentration
- From:
China Pharmacy
2024;35(2):251-256
- CountryChina
- Language:Chinese
-
Abstract:
Levetiracetam （LEV） is the second generation of broad-spectrum anti-epileptic drug. LEV has the advantages of rapid absorption， short half-life， precise efficacy， good tolerance and few drug interactions. In order to improve the clinical efficacy of LEV， and reduce the occurrence of adverse reactions， children， pregnant women， the elderly， and patients with renal insufficiency should receive therapeutic drug monitoring （TDM）. Clinically， the samples are usually plasma or serum， and the TDM methods are mostly immunoassay or chromatography. There is currently no consensus on the effective concentration range of LEV， and the correlation between plasma concentration and adverse reactions is also unclear. The main factors affecting LEV plasma concentration include age， pregnancy， and patient compliance. How to interpret TDM results and adjust dosage based on the results will be the focus of future work.
